Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
11.64
+1.28 (12.36%)
Sep 4, 2026, 4:00 PM EST
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 49 employees as of December 31, 2025. The number of employees increased by 16 or 48.48% compared to the previous year.
Employees
49
Change (1Y)
16
Growth (1Y)
48.48%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
682.79M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 49 | 16 | 48.48% | 49 | 0 |
| Dec 31, 2024 | 33 | 4 | 13.79% | 33 | 0 |
| Dec 31, 2023 | 29 | 8 | 38.10% | 29 | 0 |
| Dec 31, 2022 | 21 | 0 | - | 21 | 0 |
| Dec 31, 2021 | 21 | 9 | 75.00% | 19 | 2 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bright Minds Biosciences | 26 |
| Satellos Bioscience | 21 |
| BriaCell Therapeutics | 16 |
| Medicenna Therapeutics | 15 |
| Helix BioPharma | 7 |
Eupraxia Pharmaceuticals News
- 1 day ago - Eupraxia Pharmaceuticals management to meet with Oppenheimer - TheFly
- 16 days ago - Eupraxia Pharmaceuticals Registration statement: Registration filing - Filings
- 18 days ago - Eupraxia Pharmaceuticals reports Q2 net income ($14.5M) vs ($8.7M) last year - TheFly
- 18 days ago - Eupraxia Pharmaceuticals announces results from RESOLVE study analysis - TheFly
- 22 days ago - Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients - GlobeNewsWire
- 24 days ago - Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 24 days ago - Eupraxia Pharmaceuticals Earnings release: Q2 2026 - Filings
- 24 days ago - Eupraxia Pharmaceuticals Registration statement: Q2 2026 - Filings